Kattan J N, Villegas M V, Quinn J P
CIDEIM (International Center for Medical Research and Training), Cali, Colombia.
Clin Microbiol Infect. 2008 Dec;14(12):1102-11. doi: 10.1111/j.1469-0691.2008.02101.x.
Antibiotic resistance among Gram-negative pathogens in hospitals is a growing threat to patients and is driving the increased use of carbapenems. Carbapenems are potent members of the beta-lactam family of antibiotics, with a history of safety and efficacy for serious infections that exceeds 20 years. Original and review articles were identified from a Medline search (1979-2008). Reference citations from identified publications, abstracts from the Interscience Conferences on Antimicrobial Agents and Chemotherapy and package inserts were also used. Carbapenems are effective in treating severe infections at diverse sites, with relatively low resistance rates and a favourable safety profile. Carbapenems are the beta-lactams of choice for the treatment of infections caused by multidrug-resistant organisms. Optimized dosing of carbapenems should limit the emergence of resistance and prolong the utility of these agents. The newly approved doripenem should prove to be a valuable addition to the currently available carbapenems: imipenem, meropenem and ertapenem.
医院革兰氏阴性病原菌中的抗生素耐药性对患者构成了日益严重的威胁，并促使碳青霉烯类药物的使用增加。碳青霉烯类是β-内酰胺类抗生素中的强效成员，用于严重感染的安全性和有效性记录已有20多年。通过医学索引数据库检索（1979 - 2008年）确定了原始文章和综述文章。还使用了已确定出版物的参考文献、抗菌药物和化疗跨学科会议的摘要以及药品说明书。碳青霉烯类对治疗不同部位的严重感染有效，耐药率相对较低且安全性良好。碳青霉烯类是治疗多重耐药菌引起感染的首选β-内酰胺类药物。优化碳青霉烯类药物的给药方案应能限制耐药性的出现并延长这些药物的使用期限。新批准的多利培南应会成为现有碳青霉烯类药物（亚胺培南、美罗培南和厄他培南）中有价值的补充。
